
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytonus Therapeutics to Present Cargocyte™ Drug-Delivery Data at the ASGCT 25th Annual Meeting
Details : Cargocytes armed with interleukin 12 (CA-IL-12) can be engineered to actively home, migrate, and penetrate deep into specific disease foci and synthesize biologically active therapeutic within the target tissues, hours after intravenous administration.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results highlight the capabilities of Cytonus’ innovative Cargocyte™ platform in addressing solid tumor penetration challenges. Importantly, Cargocytes offer localized delivery of potent immunotherapies in a controlled manner to enhance their safety ...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
